Pulse Biosciences Inc (PLSE)

Currency in USD
49.79
+1.94(+4.05%)
Real-time Data·
Trading near 52-week High
PLSE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
47.4750.19
52 wk Range
12.5650.19
Key Statistics
Prev. Close
47.85
Open
47.47
Day's Range
47.47-50.19
52 wk Range
12.56-50.19
Volume
307.92K
Average Vol. (3m)
371.03K
1-Year Change
211.1875%
Book Value / Share
1.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PLSE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
45.25
Downside
-9.12%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Pulse Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 45.25
(-9.12% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Needham
Buy58.00+16.37%-New CoverageAug 17, 2026
Mizuho
Buy45.00-9.71%30.00MaintainAug 10, 2026
Canaccord
Buy43.00-13.72%32.00MaintainAug 10, 2026
Oppenheimer
Buy35.00-29.78%30.00MaintainJul 28, 2026
Canaccord
Buy32.00-35.79%-New CoverageJun 04, 2026

Pulse Biosciences Inc Earnings Call Summary for Q2/2026

  • Pulse Biosciences posted Q2 2026 adjusted loss of $0.36/share vs. $0.28 estimate; revenue of $400K missed $600K forecast by 33%, though shares rose 0.42% after hours.
  • NANOPULSE-AF pivotal trial enrollment ahead of schedule, now expected to complete early October 2026, three months early; target raised to 164 patients from 145.
  • Cash position strengthened to $101.6M at quarter-end from $68.3M prior quarter, bolstered by $46.8M ATM proceeds; company has at least five quarters of runway.
  • Non-GAAP operating expenses rose 38.5% YoY to $20.5M; management expects costs to remain in current range before rising ahead of regulatory milestones.
  • Key milestones include cardiac catheter CE mark submission H2 2026, surgical clamp CE filing by year-end 2026, and NANOCLAMP-AF study completion by H1 2027.
Last Updated: 08/06/2026, 06:02 PM
Read Full Transcript

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.36 / -0.28
Revenue / Forecast
400K / 600K
EPS Revisions
Last 90 days

PLSE Income Statement

Compare PLSE to Peers and Sector

Metrics to compare
PLSE
Peers
Sector
Relationship
P/E Ratio
−44.0x−2.1x−0.3x
PEG Ratio
4.50−0.170.00
Price / Book
35.4x3.2x2.6x
Price / LTM Sales
2,970.9x2.4x3.1x
Upside (Analyst Target)
−9.3%36.7%47.6%
Fair Value Upside
Unlock7.5%5.6%Unlock

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.41M6.37%207.16M
Other Institutional Investors
4.39M6.35%206.50M
Public Companies & Retail Investors
60.41M87.29%2.84B
Total
69.21M100.00%3.25B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.2.06%1,466,70268,964
Vanguard Capital Management, LLC1.33%946,45844,502

People Also Watch

68.690
LQDA
-3.32%
196.25
MOD
+2.89%
52.11
PENG
+1.90%
8.24
POET
-0.30%
69.230
AXTI
-5.32%

FAQ

What Is the Pulse Biosciences (PLSE) Stock Price Today?

The Pulse Biosciences stock price today is 49.79 USD.

What Stock Exchange Does Pulse Biosciences Trade On?

Pulse Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Pulse Biosciences?

The stock symbol for Pulse Biosciences is "PLSE."

What Is the Pulse Biosciences Market Cap?

As of today, Pulse Biosciences market cap is 3.56B USD.

What Is Pulse Biosciences's Earnings Per Share (TTM)?

The Pulse Biosciences EPS (TTM) is -1.18.

When Is the Next Pulse Biosciences Earnings Date?

Pulse Biosciences will release its next earnings report on Nov 16, 2026.

From a Technical Analysis Perspective, Is PLSE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Pulse Biosciences Stock Split?

Pulse Biosciences has split 0 times.

How Many Employees Does Pulse Biosciences Have?

Pulse Biosciences has 116 employees.

What is the current trading status of Pulse Biosciences (PLSE)?

As of Aug 21, 2026, Pulse Biosciences (PLSE) is trading at a price of 49.79 USD, with a previous close of 47.85 USD. The stock has fluctuated within a day range of 47.47 USD to 50.19 USD, while its 52-week range spans from 12.56 USD to 50.19 USD.

What Is Pulse Biosciences (PLSE) Price Target According to Analysts?

The average 12-month price target for Pulse Biosciences is 45.25 USD, with a high estimate of 58 USD and a low estimate of 35 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -9.12% Downside potential.

What Is the PLSE Premarket Price?

PLSE's last pre-market stock price is 48.06 USD. The pre-market share volume is 940.00, and the stock has decreased by 0.21, or 0.44%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.